论文部分内容阅读
[目的]研究拉帕替尼联合紫杉醇不同给药顺序对人胃癌细胞NCI-N87产生的不同抑制效应,探讨两者的最佳联合方案。[方法]MTT方法检测单独应用拉帕替尼、紫杉醇及两药不同联合方案对人胃癌细胞NCI-N87的增殖抑制作用,计算半数抑制浓度(IC50)和联合指数(CI),确定最佳联合方案。流式细胞技术检测拉帕替尼与紫杉醇不同给药顺序对人胃癌细胞NCI-N87细胞周期和凋亡率的影响。[结果]拉帕替尼和紫杉醇单独应用对人胃癌细胞NCI-N87均有抑制作用,而两药联合作用受给药顺序影响,紫杉醇先于拉帕替尼给药两者CI值<1表现协同效应。拉帕替尼和紫杉醇作用于胃癌细胞NCI-N87,细胞周期分别阻滞于G1期和G2-M期;两者联合时受给药顺序影响:紫杉醇先于拉帕替尼组与拉帕替尼先于紫杉醇组相比G2-M期明显延长,凋亡率显著增加。[结论 ]拉帕替尼与紫杉醇对人胃癌细胞NCIN87增殖抑制作用的最佳联合方案为先予紫杉醇诱导再序贯拉帕替尼,此方案可获得较高的凋亡率。
[Objective] To study the different inhibitory effects of different routes of administration of lapatinib and paclitaxel on human gastric cancer cell line NCI-N87 and to explore the best combination of the two. [Methods] MTT assay was used to detect the inhibitory effects of lapatinib, paclitaxel and two different regimens alone on the proliferation of human gastric cancer cell line NCI-N87. The IC50 values and the combined index (CI) were calculated to determine the best combination Program. Flow cytometry was used to detect the effect of lapatinib and taxol on the cell cycle and apoptosis of human gastric cancer cell line NCI-N87. [Results] Lapatinib and paclitaxel alone had inhibitory effects on human gastric cancer cell line NCI-N87, and the combined effect of the two drugs was affected by the order of administration. Both paclitaxel and lapatinib had CI <1 Synergy. Lapatinib and paclitaxel in gastric cancer cells NCI-N87, cell cycle arrested in the G1 phase and G2-M phase; the combination of the two affected by the order of administration: paclitaxel prior to lapatinib and lapatin Nephew first in the paclitaxel group G2-M phase was significantly prolonged, a significant increase in apoptosis. [Conclusion] The optimal combination of lapatinib and paclitaxel on human gastric cancer cell NCIN87 proliferation is the first combination of lapatinib induced by paclitaxel and the higher apoptosis rate can be obtained by this protocol.